FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of pharmaceuticals and medicine, namely, to a pharmaceutical composition for treating a brain injury and neuropsychiatric and neurodegenerative diseases and disorders, including behavioral and psychological symptoms of dementia (BPSD), containing a therapeutically effective amount of an agent with dual activity capable of inhibiting CYP2D6 and acting as an antagonist of the 5-HT2A receptor selected from the group consisting of sarpogrelate (compound 50), enantiomers thereof (compounds 51 and 52),
deuterated derivatives, pharmaceutically acceptable salts thereof, or a combination thereof; and a therapeutically effective amount of an antagonist of the NMDA receptor, constituting dextromethorphan (compound 149) or metabolites thereof selected from dextrorphan (DO), 3-hydroxymorphinan (HYM) and 3-methoxymorphinan (MEM), deuterated derivatives, pharmaceutically acceptable salts thereof, or a combination thereof, provided that the composition is a liquid composition containing 2.5 to 10 mcM of dextromethorphan; to a method for treating a brain injury and neuropsychiatric and neurodegenerative diseases and disorders, including behavioral and psychological symptoms of dementia (BPSD), including introduction of a therapeutically effective amount of said composition to a subject without an excluding condition; and to an application of the composition without an excluding condition in manufacture of a medicinal product intended for therapeutic and/or preventative treatment of a disease or disorder selected from a neuropsychiatric, neurodegenerative one, or a brain injury, including behavioral and psychological symptoms of dementia (BPSD), in a patient in need thereof, wherein said treatment involves introduction of a therapeutically effective amount of said composition targeting the CYP2D6 enzyme and the NMDA and 5-HT2A receptors.
EFFECT: group of inventions provides an improved, up to superadditive, effect of the combination and a reduction in the risk of developing side effects.
10 cl, 12 dwg, 5 tbl, 66 ex
